Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222

View ORCID ProfileThomas Perkmann, View ORCID ProfileNicole Perkmann-Nagele, Patrick Mucher, Astrid Radakovics, Manuela Repl, View ORCID ProfileThomas Koller, View ORCID ProfileGalateja Jordakieva, Oswald F Wagner, View ORCID ProfileChristoph J Binder, View ORCID ProfileHelmuth Haslacher
doi: https://doi.org/10.1101/2021.07.06.21260059
Thomas Perkmann
aDepartment of Laboratory Medicine, Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Thomas Perkmann
Nicole Perkmann-Nagele
aDepartment of Laboratory Medicine, Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicole Perkmann-Nagele
Patrick Mucher
aDepartment of Laboratory Medicine, Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Astrid Radakovics
aDepartment of Laboratory Medicine, Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuela Repl
aDepartment of Laboratory Medicine, Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Koller
aDepartment of Laboratory Medicine, Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Thomas Koller
Galateja Jordakieva
bDepartment of Physical Medicine, Rehabilitation and Occupational Medicine, Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Galateja Jordakieva
Oswald F Wagner
aDepartment of Laboratory Medicine, Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph J Binder
aDepartment of Laboratory Medicine, Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christoph J Binder
Helmuth Haslacher
aDepartment of Laboratory Medicine, Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Helmuth Haslacher
  • For correspondence: helmuth.haslacher@meduniwien.ac.at
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Objectives Our objective was to determine whether SARS-CoV-2 antibody levels after the first dose can predict the final antibody response and whether this is dependent on the vaccine type.

Methods 69 BNT162b2 (Pfizer/BioNTech) and 55 AZD1222 (AstraZeneca) vaccinees without previous infection or immunosuppressive medication were included. Anti-body levels were quantified 3 weeks after dose 1, in case of AZD1222 directly before boostering (11 weeks after dose 1) and 3 weeks after dose 2, with the Roche SARS-CoV-2 S total antibody assay.

Results Pre-booster (BNT162b2: 80.6 [25.5-167.0] BAU/mL, AZD1222: 56.4 [36.4-104.8] BAU/mL, not significant) and post-booster levels (BNT162b2: 2,092.0 [1,216.3-4,431.8] BAU/mL, AZD1222: 957.0 [684.5-1,684.8] BAU/mL, p<0.0001) correlated well in BNT162b2 (ρ=0.53) but not in AZD1222 recipients. Moreover, antibody levels after the first dose of BNT162b2 correlated inversely with age (ρ=-0.33, P=0.013), whereas a positive correlation with age was observed after the second dose in AZD1222 recipients (ρ=0.26, P=0.030).

Conclusions In conclusion, our data suggest that antibody levels quantified by the Roche Elecsys SARS-CoV-2 S assay before the booster shot could infer post-booster responses to BNT162b2, but not to AZ1222. In addition, we found a vaccine-dependent effect on antibody responses, suggesting a possible link between vaccine response and vector immunity.

Competing Interest Statement

The Department of Laboratory Medicine received compensations for advertisement on scientific symposia from Roche, and holds a grant for evaluating an in vitro diagnostic device from Roche.

Funding Statement

There was no additional funding received for the present work.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The protocol of this performance evaluation study was reviewed and approved by the Ethics committee of the Medical University of Vienna (EK 1066/2021).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data is available for interested researchers upon request in compliance with applicable data protection laws.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted July 07, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222
Thomas Perkmann, Nicole Perkmann-Nagele, Patrick Mucher, Astrid Radakovics, Manuela Repl, Thomas Koller, Galateja Jordakieva, Oswald F Wagner, Christoph J Binder, Helmuth Haslacher
medRxiv 2021.07.06.21260059; doi: https://doi.org/10.1101/2021.07.06.21260059
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222
Thomas Perkmann, Nicole Perkmann-Nagele, Patrick Mucher, Astrid Radakovics, Manuela Repl, Thomas Koller, Galateja Jordakieva, Oswald F Wagner, Christoph J Binder, Helmuth Haslacher
medRxiv 2021.07.06.21260059; doi: https://doi.org/10.1101/2021.07.06.21260059

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1256)
  • Dentistry and Oral Medicine (207)
  • Dermatology (148)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (537)
  • Epidemiology (10047)
  • Forensic Medicine (5)
  • Gastroenterology (500)
  • Genetic and Genomic Medicine (2481)
  • Geriatric Medicine (239)
  • Health Economics (482)
  • Health Informatics (1652)
  • Health Policy (756)
  • Health Systems and Quality Improvement (638)
  • Hematology (250)
  • HIV/AIDS (536)
  • Infectious Diseases (except HIV/AIDS) (11888)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2301)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (458)
  • Occupational and Environmental Health (537)
  • Oncology (1257)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (737)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2294)
  • Public and Global Health (4850)
  • Radiology and Imaging (846)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (654)
  • Rheumatology (288)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (228)
  • Surgery (271)
  • Toxicology (44)
  • Transplantation (130)
  • Urology (100)